C4 Therapeutics stock rating reiterated as Overweight by Barclays
PositiveFinancial Markets

C4 Therapeutics has received an 'Overweight' rating from Barclays, indicating strong confidence in the company's stock performance. This endorsement is significant as it reflects Barclays' belief in C4's potential for growth and success in the market, which could attract more investors and positively impact the company's valuation.
— Curated by the World Pulse Now AI Editorial System